Document is current
Any future updates will be listed below
-
Authors
Clark, Emily S.
Benaduce, Ana Paula
Khan, Wasif N.
Martinez, Olivier
Gilboa, Eli https://orcid.org/0000-0002-2645-8154
- License Information
-
More Information
Article History
Received: 5 October 2023
Accepted: 13 November 2023
First Online: 17 January 2024
Declarations
:
: The authors declare the following competing interests. EG is a founder and equity holder of Sebastian Biopharma that holds intellectual rights for inducing neoantigens by targeted downregulation of TAP.
: All animal work was conducted under the approval of the University of Miami Institutional Animal Care and Use Committee (IACUC) in accordance with federal, state, and local guidelines. Female, 10–12-week-old C57Bl/6 mice were used for all studies purchased from The Jackson Laboratory and housed in the Medical School University of Miami vivarium.
